Esaxerenone

The medication demand of global patients with chronic kidney disease complicated with hypertension has not been fully met for a long time. Traditional diuretics are prone to cause adverse reactions such as electrolyte disorder and renal function injury, which limits their long-term clinical application. As a new generation of highly selective mineralocorticoid receptor antagonist, esaxerenone specifically blocks the excessive activation of mineralocorticoid receptor mediated by aldosterone, reduces sodium and water retention and slows down the process of renal fibrosis. It can not only be used for the antihypertensive treatment of essential hypertension, but also significantly reduce the proteinuria level of patients with chronic kidney disease complicated with hypertension and delay the decline of renal function, providing a safer treatment option for hypertension population with concurrent renal injury.

The clinical value of esaxerenone rapidly drives the market expansion. In 2023, the global market size has exceeded 1.3 billion US dollars, with a compound annual growth rate of more than 42%. The domestic market is still in the early stage of development. With the improvement of the diagnosis and treatment rate of hypertension complicated with chronic kidney disease, it is estimated that the domestic market size will exceed 1.8 billion yuan in 2028. At present, the competitive landscape is still dominated by the original research products. More than 20 domestic pharmaceutical enterprises have laid out generic drug research and development, the supply gap of API is relatively obvious, and enterprises with compliant registered production capacity will occupy the first-mover advantage.

The original research enterprise of esaxerenone is Japan's Mitsubishi Tanabe Pharma, and the original research trade name is "Keshenda". Its core compound patent will expire in China in 2026, and the crystal form patent will expire in 2033. The domestically approved original research dosage form is tablet, with specifications including 25mg and 50mg, which has been included in the China Listed Medicines Catalogue as the reference preparation. Up to now, no enterprise in China has obtained the marketing approval of esaxerenone API, and there is no valid A-status registration number on the CDE API registration platform for the time being. Three domestic enterprises have submitted the marketing applications for generic preparations, which are currently in the review and approval stage. (Data as of July 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of esaxerenone impurity reference standards, covering all categories such as synthetic process impurities, degradation impurities and enantiomers. Most products are in stock, and orders placed before 16:00 can be shipped on the same day. All products meet the requirements of multiple regulatory systems such as Chinese Pharmacopoeia and FDA, and can provide stable reference material support for pharmaceutical enterprises in API process development, quality research and generic drug consistency evaluation.